Endocannabinoid System Protects Against Seizures, Study Says
Friday, August 25th, 2006From the NORML News:
Mainz, Germany: The endocannabinoid system provides “on demand” protection against experimentally induced seizures and neuronal cell death, according to preclinical data published this month in the journal Neuron.
Investigators at the Johannes Guttenberg University in Mainz and the Max Planck Institute in Munich reported that endocannabinoids, acting upon the brain’s CB1 (cannabinoid) receptors, directly target hippocampal glutamatergic neurons to mediate against experimentally induced seizures and cell death in mice. “CB1 expression on hippocampal glutamatergic circuits accounts for this protection and might represent a suitable target for the treatment of neurological disorders associated with excessive neuronal excitation,” authors concluded.
Separate preclinical studies have previously demonstrated that natural cannabinoids such as THC and cannabidiol (CBD) are neuroprotective against ethanol-induced cell death, cerebral infarction, and glutamate toxicity. Glutamate, a neurotransmitter, may be produced at toxic levels following strokes or severe head trauma often leading to irreversible brain damage.
In recent years, researchers have identified the endocannabinoid receptor system to be involved in the regulation of several primary biological functions including appetite, body temperature, mood elevation, blood pressure, bone density, embryonic implantation, learning capacity, and motor coordination.
For more information, please contact Paul Armentano, Senior Policy Analyst, at (202) 483-5500. Full text of the study, “The endocannabinoid system controls key epileptogenic circuits in the hippocampus,” appears in the August 17, 2006 edition of Neuron.
